PDF: CAE Study
(2010)Objective
Ethosuximide, valproic acid, and lamotrigine monotherapy — to compare efficacy, tolerability, and neuropsychological effects in children with newly diagnosed childhood absence epilepsy.
Study Summary
• 16-week freedom-from-treatment-failure: 53% (ethosuximide) vs 58% (valproic acid) vs 29% (lamotrigine; p<0.001 vs each).
• Attentional dysfunction (CPT) was significantly worse with valproic acid than ethosuximide (p=0.03) — a critical consideration in school-age children.
• Lamotrigine offered no tolerability advantage and worse seizure control.
• Ethosuximide emerges as the optimal first-line drug balancing efficacy and cognitive safety for this pediatric absence syndrome.
• Reshaped practice away from valproate as first-line in girls of reproductive age due to teratogenicity, with ethosuximide preferred.
Intervention
Ethosuximide, valproic acid, or lamotrigine titrated to seizure freedom, maximum tolerated dose, or treatment failure. Follow-up 16-20 weeks.
Inclusion Criteria
Children aged 2.5–13 years with newly diagnosed childhood absence epilepsy meeting ILAE criteria.
Study Design
Arms: Ethosuximide vs Valproic Acid vs Lamotrigine (1:1:1)
Patients per Arm: Ethosuximide 156; Valproic acid 148; Lamotrigine 149 (N=453)
Outcome
• Secondary: Attentional dysfunction on Conners Continuous Performance Test — valproic acid WORSE than ethosuximide (36% vs 24%; p=0.03)
• Valproic acid and ethosuximide similar on lack of seizure freedom as cause of failure
• Lamotrigine: higher failure rate dominated by incomplete seizure control
• AEs overall comparable in frequency; specific profiles differ (ethosuximide GI; valproic acid weight gain, tremor; lamotrigine rash)
Clinical Question
Which first-line monotherapy is most effective and tolerable for newly diagnosed childhood absence epilepsy?
Bottom Line
In newly diagnosed childhood absence epilepsy, ethosuximide and valproic acid produced equivalent freedom-from-treatment-failure rates at 16 weeks (~53% and 58%), both significantly better than lamotrigine (29%; p<0.001). Valproic acid caused significantly more attentional dysfunction than ethosuximide, establishing ethosuximide as the optimal first-line therapy with the best efficacy-tolerability balance in this common pediatric epilepsy syndrome.
Major Points
- Phase 3 multicenter randomized double-blind active-controlled trial
- 453 children aged 2.5-13 years with newly diagnosed childhood absence epilepsy (ILAE criteria) randomized 1:1:1
- Drugs titrated to seizure freedom, maximum tolerated dose, or treatment failure criteria
- Primary endpoint: freedom from treatment failure after 16 weeks of therapy
- Secondary endpoint: attentional dysfunction on Conners Continuous Performance Test (CPT)
- Failure defined as persistent seizures, intolerable AEs, or other discontinuation
- Freedom-from-failure: 53% ethosuximide, 58% valproic acid, 29% lamotrigine
- Ethosuximide vs lamotrigine: p<0.001
- Valproic acid vs lamotrigine: p<0.001
- Ethosuximide vs valproic acid: not significantly different (p=0.35)
- Lamotrigine failures dominated by incomplete seizure control
- Attentional dysfunction worse with valproic acid: 36% vs 24% ethosuximide (p=0.03)
- Supports ethosuximide as the optimal first-line drug balancing efficacy and cognitive tolerability
- Practice implication: valproic acid now limited in girls of reproductive age due to teratogenicity; ethosuximide preferred
- Long-term extension data showed durability of these patterns
Study Design
- Study Type
- Phase 3 multicenter randomized double-blind active-controlled trial
- Randomization
- Yes
- Blinding
- Double-blind, double-dummy
- Sample Size
- 453
- Follow-up
- 16-20 weeks per-protocol; open-label extension followed
Primary Outcome
Definition: Freedom from treatment failure at 16 weeks
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| Not applicable (3-arm comparison) | 53% ethosuximide, 58% valproic acid, 29% lamotrigine | - | p<0.001 ethosuximide vs lamotrigine; p<0.001 valproic acid vs lamotrigine; ethosuximide = valproic acid p=0.35 |
Limitations & Criticisms
- Short 16-week primary endpoint; does not assess long-term retention or seizure freedom
- Patients with mixed seizure types excluded — results don't apply to juvenile absence or absence with tonic-clonic
- Attentional dysfunction is one cognitive domain; broader cognitive effects not fully assessed
- Drug doses may have been suboptimal in some patients — slow titration
- Does not address tapering strategies and relapse after discontinuation
- Single North American population
Citation
N Engl J Med 2010;362(9):790-799